Relationship Between Serum Magnesium and Uric Acid Concentrations in Patients with Type 2 Diabetes Mellitus

Hiba A. K. AL- Hadithe

Authors

Hiba A. K. AL- Hadithe University of Fallujah - College of applied science, Department of applied Chemistry Iraq - Al_ anbar

Keywords:

Type 2 diabetes mellitus, Serum magnesium, Uric acid, Insulin resistance, Fasting serum glucose

Abstract

Diabetes type 2 is a significant public health issue, Impacting adults worldwide. The search aim to evaluate the serum level of Mg and UA and also to investigate the relationship between the two variables with other variables used in the research in type 2 diabetes patients. Sixty samples were included in this study, they were divided into two groups; controls group which involved 30 persons , and patients group involved 30 persons , the sample collection has been attended from Abu Ghureb General hospital and some private laboratories in Al-Fallujah city, for the sampling period was from December 2022 to April 2023 and the ages of all samples was ranged from 30-90 year. The study quoted the levels of Magnesium, Uric acid and Glucose in serum. The findings indicated that there is statistically significant difference between infected and non-infected individuals with regard to weight gain and age increase, therefore, there is a higher possibility of getting diabetes as age increase and weight gain is increased. Concerning height, we do recognise that those who are more tall are people that are not as prone to diabetes as those who are shorter. When it comes to body mass indexes, this results in an enhanced chance of acquiring diabetes. The infected fasting person has a higher blood sugar level than healthy people. As for both magnesium, uric acid , and glucose , the percentage of magnesium in infected people is lower than that of healthy people. That people who have diabetes have high levels of both uric acid and glucose.

References

J. Wang, W. Gu, and C. Chen, “Knocking down insulin receptor in pancreatic beta cell lines with lentiviral-small hairpin RNA reduces glucose-stimulated insulin secretion via decreasing the gene expression of insulin, GLUT2 and Pdx1,” Int. J. Mol. Sci., vol. 19, no. 4, Art. no. 985, 2018.

D. Ferguson and B. N. Finck, “Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus,” Nat. Rev. Endocrinol., vol. 17, no. 8, pp. 484–495, 2021.

“Current Vascular Pharmacology,” vol. 18, no. 2, pp. 117–124, 2020.

M. J. Davies, V. R. Aroda, B. S. Collins, R. A. Gabbay, J. Green, N. M. Maruthur, et al., “Management of hyperglycemia in type 2 diabetes, 2022: A consensus report by the ADA and EASD,” Diabetes Care, vol. 45, no. 11, pp. 2753–2786, 2022.

“Type 2 Diabetes: Causes, Diagnosis and Management,” Jan. 30, 2017.

F. Q. Nuttall, “BMI: Obesity, BMI, and health: Critical review,” Nutrition Today, vol. 50, no. 3, pp. 117–128, 2015.

G. A. Bray, M. D. Vollmer, J. P. et al., “Relation of central adiposity and body mass index to the development of diabetes in the Diabetes Prevention Program,” Am. J. Clin. Nutr., vol. 87, no. 5, pp. 1212–1218, 2008.

R. Jacob, et al., “Frequency of orthopedic manifestations in COVID-19 patients,” J. Taibah Univ. Med. Sci., vol. 17, no. 2, pp. 186–192, 2022.

Q. Qiao and R. Nyamdorj, “Is the association of type II diabetes with waist circumference or waist-to-hip ratio stronger than that with body mass index?,” Eur. J. Clin. Nutr., vol. 64, no. 1, pp. 30–34, 2010.

P. Kumar, S. Bhargava, P. K. Agarwal, A. Garg, and A. Khosla, “Association of serum magnesium with type 2 diabetes mellitus and diabetic retinopathy,” J. Family Med. Prim. Care, vol. 8, no. 5, pp. 1671–1677, 2019.

M. de Lourdes Lima, T. Cruz, J. C. Pousada, L. E. Rodrigues, K. Barbosa, and V. Canguçu, “The effect of magnesium supplementation in increasing doses on the control of type 2 diabetes,” Diabetes Care, vol. 21, no. 5, pp. 682–686, 1998.

K. Nakajima, “Low serum amylase and obesity, diabetes and metabolic syndrome: A novel interpretation,” World J. Diabetes, vol. 7, no. 6, pp. 112–121, 2016.

H. Yaribeygi, F. R. Farrokhi, A. E. Butler, and A. Sahebkar, “Insulin resistance: Review of the underlying molecular mechanisms,” J. Cell. Physiol., vol. 234, no. 6, pp. 8152–8161, 2019.

J. P. Bae, M. J. Lage, D. Mo, D. R. Nelson, and B. J. Hoogwerf, “Obesity and glycemic control in patients with diabetes mellitus,” J. Diabetes Complications, vol. 30, no. 2, pp. 212–220, 2016.

A. Čaušević, S. Semiz, A. Macić-Džanković, et al., “Relevance of uric acid in progression of type 2 diabetes mellitus,” Bosn. J. Basic Med. Sci., vol. 10, no. 1, pp. 54–59, 2010.

J. B. Chang, Y. L. Chen, Y. J. Hung, et al., “The role of uric acid for predicting future metabolic syndrome and type 2 diabetes in older people,” J. Nutr. Health Aging, vol. 21, no. 3, pp. 329–335, 2017.

A. Lecube, J. A. Baena-Fustegueras, J. M. Fort, D. Pelegrí, C. Hernández, and R. Simó, “Diabetes is the main factor accounting for hypomagnesemia in obese subjects,” PLoS One, vol. 7, no. 1, Art. no. e30599, 2012.

M. Abdullah, et al., “Prevalence and determinants of hypomagnesemia in adults with type 2 diabetes mellitus,” BMC Endocr. Disord., 2025.

M. R. Xu, et al., “Serum magnesium levels are negatively associated with obesity and metabolic abnormalities in patients with type 2 diabetes mellitus,” Diabetes Metab. J., 2024.

A. Pitliya, et al., “Global prevalence of hypomagnesemia in type 2 diabetes mellitus: A systematic review and meta-analysis,” Endocrine, 2024.

S. Jain, et al., “Association of serum magnesium, serum uric acid levels, and microalbuminuria in patients with type 2 diabetes mellitus,” Int. J. Adv. Med., vol. 9, pp. 783–788, 2022.

K. Alswat, et al., “Type 2 diabetes control and complications and their relationship with serum magnesium concentrations,” Arch. Med. Sci., vol. 18, pp. 307–313, 2022.

D. P. Chaudhary, R. Sharma, and D. D. Bansal, “Implications of magnesium deficiency in type 2 diabetes: A review,” Biol. Trace Elem. Res., vol. 134, no. 2, pp. 119–129, 2010.

L. M. M. Gommers, J. G. J. Hoenderop, R. J. M. Bindels, and J. H. F. de Baaij, “Hypomagnesemia in type 2 diabetes: A vicious circle?,” Diabetes, vol. 65, no. 1, pp. 3–13, 2016.

E. J. Xu, et al., “Hypomagnesemia with metformin use in diabetes mellitus: Mechanisms and clinical implications,” Diabetes Metab. Syndr., 2025.

A. K. Rodrigues, et al., “Association between reduced serum magnesium levels and poor glycemic control in patients with type 2 diabetes mellitus: A systematic review,” Diabetes Metab. Syndr., vol. 14, pp. 1277–1284, 2020.

M. de Lourdes Lima, T. Cruz, J. C. Pousada, L. E. Rodrigues, K. Barbosa, and V. Canguçu, “Serum and intracellular magnesium deficiency in patients with metabolic syndrome,” Diabetes Res. Clin. Pract., vol. 83, no. 2, pp. 257–262, 2009.

R. P. Kauffman, P. E. Tullar, R. D. Nipp, and V. D. Castracane, “Serum magnesium concentrations and metabolic variables in obese women,” Magnes. Res., vol. 24, no. 2, pp. 48–53, 2011.

D. Simmons, S. Joshi, and J. Shaw, “Hypomagnesemia is associated with diabetes but not prediabetes, obesity, or metabolic syndrome,” Diabetes Res. Clin. Pract., vol. 87, no. 2, pp. 261–266, 2010.

Q. Lv, X. F. Meng, F. F. He, et al., “High serum uric acid and increased risk of type 2 diabetes: A systematic review and meta-analysis of prospective cohort studies,” PLoS One, vol. 8, no. 2, Art. no. e56864, 2013.

R. J. Johnson, T. Nakagawa, L. G. Sanchez-Lozada, et al., “Sugar, uric acid, and the etiology of diabetes and obesity,” Diabetes, vol. 62, no. 10, pp. 3307–3315, 2013.

Y. L. Xu, K. F. Xu, J. L. Bai, et al., “Elevation of serum uric acid and incidence of type 2 diabetes: A systematic review and meta-analysis,” Chronic Dis. Transl. Med., vol. 2, no. 2, pp. 81–91, 2016.

D. S. Kumar, et al., “Correlation of fasting serum uric acid with fasting blood glucose and glycemic status in type 2 diabetes mellitus,” Eur. J. Cardiovasc. Med., 2025.

H. Nan, Y. Dong, W. Gao, J. Tuomilehto, and Q. Qiao, “Diabetes associated with a low serum uric acid level in a general Chinese population,” Diabetes Res. Clin. Pract., vol. 76, no. 1, pp. 68–74, 2007.

S. Navin, N. Krishnamurthy, S. Ashakiran, and C. D. Dayanand, “The association of hypomagnesemia, high-normal uric acid, and dyslipidemia in the development of diabetic complications,” Int. J. Diabetes Dev. Ctries., vol. 33, pp. 179–185, 2013.